

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - NCI releases names of members of ad hoc working group—filling the void left by BSA
- ACOG says it will no longer accept federal funding
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - Bhattacharya: New grant review criterion is “not political”
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer